149 related articles for article (PubMed ID: 35352020)
1. Investigation of urinary volatile organic compounds as novel diagnostic and surveillance biomarkers of bladder cancer.
Lett L; George M; Slater R; De Lacy Costello B; Ratcliffe N; García-Fiñana M; Lazarowicz H; Probert C
Br J Cancer; 2022 Jul; 127(2):329-336. PubMed ID: 35352020
[TBL] [Abstract][Full Text] [Related]
2. Pilot study for bladder cancer detection with volatile organic compounds using ion mobility spectrometry: a novel urine-based approach.
Heers H; Gut JM; Hofmann R; Flegar L; Derigs M; Huber J; Baumbach JI; Koczulla AR; Boeselt T
World J Urol; 2024 May; 42(1):353. PubMed ID: 38795133
[TBL] [Abstract][Full Text] [Related]
3. Qualitative and quantitative detection of urinary human complement factor H-related protein (BTA stat and BTA TRAK) and fragments of cytokeratins 8, 18 (UBC rapid and UBC IRMA) as markers for transitional cell carcinoma of the bladder.
Babjuk M; Kostírová M; Mudra K; Pecher S; Smolová H; Pecen L; Ibrahim Z; Dvorácek J; Jarolím L; Novák J; Zima T
Eur Urol; 2002 Jan; 41(1):34-9. PubMed ID: 11999463
[TBL] [Abstract][Full Text] [Related]
4. "Seeing" invisible volatile organic compound (VOC) marker of urinary bladder cancer: A development from bench to bedside prototype spectroscopic device.
Bhattacharyya N; Mukherjee D; Singh S; Ghosh R; Karmakar S; Mallick A; Chattopadhyay A; Mondal P; Mondal T; Bhattacharyya D; Mallick AK; Nabi G; Pal SK
Biosens Bioelectron; 2022 Dec; 218():114764. PubMed ID: 36206669
[TBL] [Abstract][Full Text] [Related]
5. An early analysis of the cost-effectiveness of a diagnostic classifier for risk stratification of haematuria patients (DCRSHP) compared to flexible cystoscopy in the diagnosis of bladder cancer.
Sutton AJ; Lamont JV; Evans RM; Williamson K; O'Rourke D; Duggan B; Sagoo GS; Reid CN; Ruddock MW
PLoS One; 2018; 13(8):e0202796. PubMed ID: 30138462
[TBL] [Abstract][Full Text] [Related]
6. Development of a headspace-solid phase microextraction gas chromatography-high resolution mass spectrometry method for analyzing volatile organic compounds in urine: Application in breast cancer biomarker discovery.
Li X; Wen X; Luo Z; Tian Y; Qian C; Zhang J; Ling R; Duan Y
Clin Chim Acta; 2023 Feb; 540():117236. PubMed ID: 36716910
[TBL] [Abstract][Full Text] [Related]
7. Urinary UBC Rapid and NMP22 Test for Bladder Cancer Surveillance in Comparison to Urinary Cytology: Results from a Prospective Single-Center Study.
Pichler R; Tulchiner G; Fritz J; Schaefer G; Horninger W; Heidegger I
Int J Med Sci; 2017; 14(9):811-819. PubMed ID: 28824318
[No Abstract] [Full Text] [Related]
8. GC-MS metabolomics-based approach for the identification of a potential VOC-biomarker panel in the urine of renal cell carcinoma patients.
Monteiro M; Moreira N; Pinto J; Pires-Luís AS; Henrique R; Jerónimo C; Bastos ML; Gil AM; Carvalho M; Guedes de Pinho P
J Cell Mol Med; 2017 Sep; 21(9):2092-2105. PubMed ID: 28378454
[TBL] [Abstract][Full Text] [Related]
9. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
[TBL] [Abstract][Full Text] [Related]
10. Comparison of two qualitative assays, the UBC rapid test and the BTA stat test, in the diagnosis of urothelial cell carcinoma of the bladder.
Mian C; Lodde M; Haitel A; Egarter Vigl E; Marberger M; Pycha A
Urology; 2000 Aug; 56(2):228-31. PubMed ID: 10925083
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the monoclonal UBC-ELISA test and the NMP22 ELISA test for the detection of urothelial cell carcinoma of the bladder.
Mian C; Lodde M; Haitel A; Vigl EE; Marberger M; Pycha A
Urology; 2000 Feb; 55(2):223-6. PubMed ID: 10688083
[TBL] [Abstract][Full Text] [Related]
12. Urinary Molecular Pathology for Patients with Newly Diagnosed Urothelial Bladder Cancer.
Zhang R; Zang J; Xie F; Zhang Y; Wang Y; Jing Y; Zhang Y; Chen Z; Shahatiaili A; Cai MC; Zhao Z; Du P; Jia S; Zhuang G; Chen H
J Urol; 2021 Oct; 206(4):873-884. PubMed ID: 34061567
[TBL] [Abstract][Full Text] [Related]
13. Non-invasive Detection of Bladder Tumors Through Volatile Organic Compounds: A Pilot Study with an Electronic Nose.
Heers H; Gut JM; Hegele A; Hofmann R; Boeselt T; Hattesohl A; Koczulla AR
Anticancer Res; 2018 Feb; 38(2):833-837. PubMed ID: 29374709
[TBL] [Abstract][Full Text] [Related]
14. Urinary bladder cancer test: a new urinary tumor marker in the follow-up of superficial bladder cancer.
Mungan NA; Vriesema JL; Thomas CM; Kiemeney LA; Witjes JA
Urology; 2000 Nov; 56(5):787-92. PubMed ID: 11068302
[TBL] [Abstract][Full Text] [Related]
15. Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study.
Frantzi M; van Kessel KE; Zwarthoff EC; Marquez M; Rava M; Malats N; Merseburger AS; Katafigiotis I; Stravodimos K; Mullen W; Zoidakis J; Makridakis M; Pejchinovski M; Critselis E; Lichtinghagen R; Brand K; Dakna M; Roubelakis MG; Theodorescu D; Vlahou A; Mischak H; Anagnou NP
Clin Cancer Res; 2016 Aug; 22(16):4077-86. PubMed ID: 27026199
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the clinical value of urinary NMP22 as a marker in the screening and surveillance of transitional cell carcinoma of the urinary bladder.
Chahal R; Darshane A; Browning AJ; Sundaram SK
Eur Urol; 2001 Oct; 40(4):415-20; discussion 421. PubMed ID: 11713396
[TBL] [Abstract][Full Text] [Related]
17. Urine markers for bladder cancer surveillance: a systematic review.
van Rhijn BW; van der Poel HG; van der Kwast TH
Eur Urol; 2005 Jun; 47(6):736-48. PubMed ID: 15925067
[TBL] [Abstract][Full Text] [Related]
18. [Clinical value of combined detection with urinary bladder cancer antigen, hyaluronic acid and cytokeratin 20 in diagnosis of bladder cancer].
Pu XY; Wang ZP; Chen YR; Wu YL; Wang HP; Wang XH
Ai Zheng; 2008 Sep; 27(9):970-3. PubMed ID: 18799038
[TBL] [Abstract][Full Text] [Related]
19. Urinary protein biomarker panel for the detection of recurrent bladder cancer.
Rosser CJ; Chang M; Dai Y; Ross S; Mengual L; Alcaraz A; Goodison S
Cancer Epidemiol Biomarkers Prev; 2014 Jul; 23(7):1340-5. PubMed ID: 24714076
[TBL] [Abstract][Full Text] [Related]
20. Pre and postoperative quantitative detection of fragments of cytokeratins 8 and 18 (UBC IRMA) as markers of early recurrence of superficial bladder tumor.
Gacci M; Serni S; Lapini A; Giubilei G; Dal Canto M; Paladini S; Curotto A; Gallo F; Carmignani G; Carini M
Arch Ital Urol Androl; 2006 Mar; 78(1):5-10. PubMed ID: 16752880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
